## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.0% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($10.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Behavioral Patterns of VTRS and Institutional Flows**
- Source: Stock Traders Daily | 20251201T174400 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Viatris Inc. (NASDAQ: VTRS) through its behavioral patterns and institutional flows, as of December 1, 2025. It highlights strong near-term sentiment while mid and long-term outlooks remain neutral, with resistance being tested. The analysis provides specific AI-generated trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

**2. |Viatris, Inc. Trade Ideas — SIX:VTRS.USD**
- Source: TradingView | 20251201T085151 | Bullish | Relevance: 100%
- |This compilation of trade ideas for Viatris, Inc. (VTRS.USD SIX Swiss Exchange) presents various analyses ranging from long-term dividend plays and Fibonacci analysis for entry points to short-term trading signals and comparative analyses with other pharmaceutical stocks like MRK. Analysts provide specific price targets, stop losses, and entry points, utilizing technical indicators like SMA, ATR Keltner Channel, and Elliot Wave theory, while also discussing sentiment and fundamental considerations.

**3. Viatris Inc. Reports Steady Q3 2025 Performance**
- Source: MSN | 20251201T085151 | Somewhat-Bullish | Relevance: 100%
- Viatris Inc. (VTRS) announced steady performance for Q3 2025, with revenues largely meeting expectations despite a slight year-over-year decrease. The company reaffirmed its full-year 2025 guidance and highlighted progress in its strategic initiatives, including deleveraging and portfolio optimization.

**4. Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields**
- Source: Benzinga | 20251201T083000 | Somewhat-Bullish | Relevance: 83%
- This article highlights three health care stocks—CVS Health, Viatris Inc, and Bristol-Myers Squibb Co—that offer high dividend yields and have received recent analyst ratings. It details the dividend yield for each company, recent analyst actions including rating maintenances, upgrades, and price target adjustments, and their accuracy rates. The piece also includes recent news updates for each company, emphasizing their performance and strategic developments.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.07 indicates undervaluation relative to growth. Forward P/E 4.4x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.68 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.07 |
| Forward P/E | 4.4 |
| Current P/E | 4.7 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 1.0% (minimal 5-day change). Below STRENGTH zone by 3.0pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.01% (CS: 62) | Neutral |
| RSI_14 | 58.8 | Neutral |
| MACD Histogram | 0.00 | Bearish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 1.145x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $10.84
- **Stop Loss:** $10.30 (5.0% risk)
- **Target:** $11.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1759
- **Position Value:** $19,067.56
- **Portfolio %:** 19.07%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*